Characterization of the Avian Progesterone Receptor Through the Use of Inhibitors

  • David Toft
  • P. Elaine Roberts
  • Hideo Nishigori
  • Virinder K. Moudgil
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 117)


Several chemical agents have been identified which block interaction of the avian progesterone receptor with isolated nuclei, ATP-Sepharose, DNA-cellulose or phosphocellulose. Four of these inhibitors, rifamycin AF/013, o-phenanthroline, aurintricarboxylic acid and pyridoxal 5-phosphate appear to block directly binding of the activated receptor complex to the above “acceptors.” Another inhibitor, sodium molybdate, only blocks receptor interactions when added before receptor activation and therefore appears to interfere with the activation process. When nuclear receptor complexes were formed in vivo and labeled by nuclear exchange with [3H]progesterone in vitro these complexes could not be disrupted by incubation of the nuclei with inhibitors. Therefore, the receptor complex bound in nuclei appears to be modified or masked in a way which resists the action of these chemical agents. These results indicate the value of inhibitors as chemical probes for the analysis of steroid receptors.


Progesterone Receptor Receptor Complex Pyridoxal Phosphate Sodium Molybdate Nuclear Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lohmar, P. H. and Toft, D. O. (1975). Biochem. Biophys. Res. Commun. 67: 8.Google Scholar
  2. 2.
    Toft, D., Lohmar, P., Miller, J., and Moudgil, V. (1976). J. Steroid Biochem. 7: 1053.PubMedCrossRefGoogle Scholar
  3. 3.
    Toft, D., Moudgil, V., Lohmar N.Y. Acad. Sci. 286:29., P., and Miller, J. (1977). Ann.Google Scholar
  4. 4.
    Moudgil, V. K. and Eessalu, T. E. (1978). Fed. Proc. 37: 284.Google Scholar
  5. 5.
    Moudgil, V. K. and Eessalu, T. and Toft, D. (1978). Biochem.Google Scholar
  6. 6.
    Nishigori, H., Moudgil, V. K., Biophys. Res. Commun. 80:112. E. (1978). Fed. Proc. 37: 1315Google Scholar
  7. 7.
    Moudgil, V. K. and Toft, D. 0. (1975). Proc. Nat. Acad. Sci. USA 72: 901.Google Scholar
  8. 8.
    Burton, K. (1956). Biochem. J. 62: 315.PubMedGoogle Scholar
  9. 9.
    Miller, J. B. and Toft, D. 0. (1978). Biochemistry 17: 173.PubMedCrossRefGoogle Scholar
  10. 10.
    Schrader, W. T., Heuer, S. S., and O’Malley, B. W. (1975). Biol. Reproduct. 12: 134.CrossRefGoogle Scholar
  11. 11.
    Nielsen, C. J., Vogel, W. M., and Pratt, W. B. (1977). Cancer Res. 37: 3420.PubMedGoogle Scholar
  12. 12.
    Nielsen, C. J., Sando, J. J., Vogel, W. M., and Pratt W. B. (1977). J. Biol. Chem. 252: 7568.Google Scholar
  13. 13.
    Mester, M. and Baulieu, E.-E. (1977). Eur. J. Biochem. 72: 405.PubMedCrossRefGoogle Scholar
  14. 14.
    Andre, J., Pfeiffer, A., and Rochefort, H. (1976). Biochemistry 15: 2964.PubMedCrossRefGoogle Scholar
  15. 15.
    Andre, J., Vic, P., Humeau, C., and Rochefort, H. (1977). Molec. Cell. Endocrinol. 8: 225.Google Scholar

Copyright information

© Springer Science+Business Media New York 1979

Authors and Affiliations

  • David Toft
    • 1
  • P. Elaine Roberts
    • 1
  • Hideo Nishigori
    • 1
  • Virinder K. Moudgil
    • 1
  1. 1.Department of Molecular MedicineMayo Medical SchoolRochesterUSA

Personalised recommendations